|
 |
|
Minister Austin Gatt, described Siegfried’s investment in Malta as an important investment from Switzerland in Malta. The presence of Siegfried in Malta will contribute to Malta’s attraction as a pharmaceutical destination. This is because of the strength of the Siegfried brand name in the industry.
Speaking during the launch of the company’s new operation in Malta, the minister explained that Malta is achieving success in the pharmaceutical industry and today we have 11 companies involved in this sector, employing over 600 employees between them.
Siegfried will be using its Malta plant to produce very high value-added generic pharmaceuticals. Siegfried has brought to Malta, the latest technology (equipment) in the pharmaceutical sector because the product they produce is a very sophisticated type of generic. By the end June Siegfried will increase its employees by 15. These jobs are high salary jobs, testimony that our economy is producing not just more, but better jobs.
Dr. Markus Altwegg, Chairman of the Board of Directors said that before the company started the construction and planning of this plant, the company has reviewed several possible other locations for it in Asia, in Eastern Europe, in Spain and in Portugal. However “at the end, we clearly decided to invest here.” He highlighted the quality of the Maltese resources and the support it got from Malta Enterprise as key factors for the success of Siegfried in Malta. He also announced that the company is also validating the second phase of their presence in Malta.
He added “Our planning go further, and this future planning wouldn’t be possible if we where not fully satisfied with the Maltese location and particularly with the support, the sense of reliability, responsiveness and sympathy shown by the authorities and the individuals who stand behind their various organisations. |
